- Home
- ELBM vs OVID Comparison
ELBM vs OVID Comparison
Compare ELBM & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | OVID |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 117.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ELBM | OVID |
|---|---|---|
| Price | $0.93 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.15 | ★ $3.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $0.77 | $0.24 |
| 52 Week High | $8.70 | $2.01 |
Technical Indicators
Market Signals| Indicator | ELBM | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 56.72 |
| Support Level | $0.97 | $1.54 |
| Resistance Level | $1.10 | $1.75 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 35.99 | 55.01 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.